A company is developing Gozzellix, a next-generation PSMA-PET imaging agent, for prostate cancer treatment, benefiting from Trump-era tariffs and AI stocks.
2 reports, 2 independent
Updated Jul 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company is developing Gozzellix, a next-generation PSMA-PET imaging agent, for prostate cancer treatment, benefiting from Trump-era tariffs and AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Strategic research partnership established in the US between TELIX PHARMACEUTICALS LIMITED and United Imaging Healthcare.Sub-event
TELIX leverages Trump-era tariffs and AI stocks for its Gozzellix prostate cancer agent.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- Insider MonkeyTelix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Fun
- GlobeNewswireGozellix Receives Permanent HCPCS Code MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its